Synthetic lethal strategies targeting DNA repair defects, using small molecule inhibitors such as PARP inhibitors, are shedding light on cancer treatment with low adverse-effects and more tumor-selective killing [82]. This evidence concerns the gene PARP1 and neoplasm.